BRCA1 and cancer: In this scenario, Strickland et al. [23] proved significantly higher predicted neoantigens, TILs density and PD-1/PDL-1 expression in BRCA1/2-mutated ovarian tumors when compared to cancers without alterations in homologous recombination genes.